ACON
Aclarion, Inc.
Key Financials
Net Income
$-7233629
↓ 3.4%
Operating Income
$-7052391
↓ 27.9%
Gross Profit
$6828
↑ 117.5%
Revenue
$75730
↑ 65.6%
EPS (Diluted)
$-13.61
↑ 99.8%
Cash & Equivalents
$12.0M
↑ 2548.6%
Total Liabilities
$837287.00
↓ 27.4%
Total Assets
$13.7M
↑ 543.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| PRE 14A | 4/3/2026 | View on SEC |
| SCHEDULE 13G | 3/25/2026 | View on SEC |
| 8-K | 3/19/2026 | View on SEC |
| 8-A12B | 3/19/2026 | View on SEC |
| 10-K | 3/18/2026 | View on SEC |
| 8-K | 1/13/2026 | View on SEC |
| 8-K | 1/9/2026 | View on SEC |
| 424B5 | 1/9/2026 | View on SEC |
| 4 | 12/1/2025 | View on SEC |
| 10-Q | 11/12/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ACON |
| Company Name | Aclarion, Inc. |
| CIK | 1635077 |
| Sector | Services-Medical Laboratories |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 8071 |
| SIC Description | Services-Medical Laboratories |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 833 275 2266 |